WHAT KAISER REQUIRES FIRST Step Therapy Requirements Even in regions where Kaiser covers Zepbound, you must typically "fail" multiple other treatments first: Kaiser Northwest Example (Most Documented) To qualify for Zepbound coverage in Kaiser Northwest, you must demonstrate: [3] Kaiser Zepbound Coverage Criteria BMI 30 (obesity) OR BMI 27 with a comorbidity (hypertension, diabetes, high cholesterol) Age 18+ Following a structured diet and exercise program (documented, not just attested) Failed at least 2 prior weight loss medications : Phentermine Diethylpropion Qsymia (phentermine/topiramate) Contrave (naltrexone/bupropion) Tried semaglutide (Wegovy or Ozempic) for minimum 6 months and either: It was ineffective (didn't achieve target weight loss) Cannot tolerate due to allergy, serious side effects, or contraindication Continuation Requirements (To Keep Coverage) Initial approval typically for 12 months Must document at least 5% weight loss after starting tirzepatide to continue coverage Bariatric medicine chart review required before switching from semaglutide to Zepbound Kaiser's Internal "Medical Weight Management" Program Kaiser often requires patients to enroll in their internal weight management program before approving GLP-1s
Its role in promoting a balanced internal environment has been widely studied
Consult with qualified professionals and institutional review boards before initiating any research involving these compounds
Include more of the following in your diet: Monounsaturated fatty acids (MUFAs), such as those found in avocados and olive oil Omega-3 fatty acids, which are abundant in flaxseeds, chia seeds, and walnuts Many plant-based protein powders now include these healthy fats to enhance satiety and optimize nutrient absorption
One study measuring skeletal muscle mass in older adults (aged 55 - 70) showed that taking a supplement containing L-Carnitine (1500 mg), L-leucine (2000 mg), creatine (3000 mg), and Vitamin D3 (10 g) for 8 weeks showed a 1.0 kg increase in total lean muscle mass (14)
Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding
